

On page 6, line 12, after "KRRLIFSK" please insert --(SEQ ID NO:13)--.

On page 8, line 3, after "KxxRRyFzP" please insert --(SEQ ID NO:14)--.

On page 10, line 5, after "RQIKIWFQNRRMKWKK" please insert --(SEQ ID NO:5)--.

On page 43, line 27, after "peptide." please insert --Peptides 1-11 correspond with SEQ ID NO:1 to SEQ ID NO:11 respectively.--

On page 45, line 15, after "(KRRLIFS)" please insert --(SEQ ID NO:23)--.

On page 45, line 3, after "autoradiography" please insert --(Peptide a corresponds with SEQ ID NO:16; peptide b corresponds with SEQ ID NO:17; peptide c corresponds with SEQ ID NO:18; peptide d corresponds with SEQ ID NO:19; peptide e corresponds with SEQ ID NO:20; peptide 10 corresponds with SEQ ID NO:10; peptide f corresponds with SEQ ID NO:21; and peptide g corresponds with SEQ ID NO:22.--

On page 47, line 9, after "Rb protein." Please insert --Peptide I corresponds with SEQ ID NO:24; peptide II corresponds with SEQ ID NO:25; and peptide III corresponds with SEQ ID NO:26.--

On page 62, line 16, after "QTSMTDFY" please insert --(SEQ ID NO:27)--.

On page 63, line 17, after "RRLIF" please insert --(SEQ ID NO: 12)--

On page 65, line 28, after "KRRLIFSK" please insert --(SEQ ID NO:23)--

On page 75, line 20, after "(KRRLIFSK)" please insert --(SEQ ID NO:23)--

In the Claims

Please cancel claims 1, 13-16, 18-29, and 30 without prejudice. Please amend the claims as follows (all of the claims, whether or not amended are presented below for the convenience of the Examiner):

2. (Twice Amended) A method for identifying a compound which modulates interaction or binding between p21 and cyclin D1 and/or Cdk 4, the method including: